-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A7XDLSGgUTu+T70OUAi+ZzEi5l2PdAmgbAbhz+YEhvZ4Lg4H7iB//FWdH+YL3in8 RLPChc1eeoZZw3GyYKtxIg== 0000950134-99-002748.txt : 19990408 0000950134-99-002748.hdr.sgml : 19990408 ACCESSION NUMBER: 0000950134-99-002748 CONFORMED SUBMISSION TYPE: 10KSB40/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19981231 FILED AS OF DATE: 19990407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMARILLO BIOSCIENCES INC CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10KSB40/A SEC ACT: SEC FILE NUMBER: 000-20791 FILM NUMBER: 99588562 BUSINESS ADDRESS: STREET 1: 800 W 9TH AVE CITY: AMARILLO STATE: TX ZIP: 79101-3206 BUSINESS PHONE: 8063761741 MAIL ADDRESS: STREET 1: AMARILLO BIOSCIENCES INC STREET 2: 800 W 9TH AVE CITY: AMARILLO STATE: TX ZIP: 79101-3206 10KSB40/A 1 AMENDMENT NO. 1 TO FORM 10KSB FYE 12/31/98 1 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 1998 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 0-20791 AMARILLO BIOSCIENCES, INC. (NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER) TEXAS 75-1974352 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 800 WEST 9TH AVENUE, AMARILLO, TEXAS 79101 (Address of principal executive offices) (Zip Code) ISSUER'S TELEPHONE NUMBER, INCLUDING AREA CODE: (806) 376-1741 Securities registered under Section 12(b) of the Exchange Act: None. Securities registered under Section 12(g) of the Exchange Act: Common Stock, Par Value $.01 (Title of class) Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [X] Revenues for its most recent fiscal year were $222,289 As of March 9, 1999, there were outstanding 5,414,232 shares of the registrant's common stock, par value $.01, which is the only class of common or voting stock of the registrant. As of that date, the aggregate market value of the shares of common stock held by nonaffiliates of the registrant (based on the closing price for the common stock on the NASDAQ SmallCap Market) was approximately $6,458,412. 2 ITEM 10. EXECUTIVE COMPENSATION. The following table sets forth for the three years ended December 31, 1998 compensation paid by the Company to its Chairman of the Board, President and Chief Executive Officer, and to its former Executive Vice-President and Chief Financial Officer. None of the Company's other executive officers had annual salary and bonus in excess of $100,000 for services rendered during any of the three years ended December 31, 1998. SUMMARY COMPENSATION TABLE
Annual Compensation ------------------------------------------------------------ NAME AND PRINCIPAL POSITION YEAR SALARY BONUS OTHER COMPENSATION - ------------------------------------------ ---- ----------------- ------------ -------------------- Dr. Joseph Cummins, Chairman -- of the Board, President and Chief Executive Officer.............. 1998 $ 150,000 $ -- $ 1997 120,000 20,000 12,000(3) 1996 120,000 -- 252,000(4) Charles Hughes, Executive Vice- President and Chief Financial Officer (1).......................... 1998 -- -- -- 1997 147,435 (2) -- 10,333(3) 1996 75,000 10,000 157,575(5)
(1) Mr. Hughes terminated his employment with the Company on September 8, 1997. (2) Includes both 1997 salary and severance payments. (3) Represents a Company contribution to the Simplified Employee Pension Plan. (4) Represents the value of 30,000 shares of common stock issued at $5.00 per share and payment of withholding tax requirements in settlement of restricted stock grants and a Company contribution of $12,000 to the Simplified Employee Pension Plan. (5) Represents the value of 19,000 shares of common stock issued at $5.00 per share and payment of withholding tax requirements in settlement of restricted stock grants and a Company contribution of $7,500 to the Simplified Employee Pension Plan. 2 3 OPTION GRANTS IN 1998 The following table sets forth certain information relating to options granted in 1998 to the executive officers named above, to purchase shares of common stock of the Company.
NUMBER OF SHARES OF COMMON STOCK % OF TOTAL UNDERLYING OPTIONS GRANTED EXERCISE OR OPTIONS TO EMPLOYEES BASE PRICE EXPIRATION NAME GRANTED(#) IN 1997 ($/SH) DATE - ----------------------------------------- ------------ --------------- ----------- ---------- John Smith............................... 40,000 67.8% $1.75 (1) 09/13/2008
(1) The fair market value of the common stock on the date of the grant. AGGREGATED OPTION EXERCISES AT DECEMBER 31, 1998 AND YEAR-END OPTION VALUES The following table sets forth information for the executive officers named above, regarding the exercise of options during 1998 and unexercised options held at the end of 1998.
NUMBER OF SHARES OF VALUE OF UNEXERCISED COMMON STOCK UNDERLYING IN-THE-MONEY SHARES UNEXERCISED OPTIONS AT OPTIONS AT ACQUIRED ON VALUE DECEMBER 31, 1998(#) DECEMBER 31, 1998($)(1) NAME EXERCISE(#) REALIZED($) EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE - ------------------------------- ------------- ------------ ------------------------- ------------------------- Joseph Cummins -- -- 5,500 / 9,000 None / None John Smith -- -- -- / 40,000 None / None
(1) Calculated based on the closing price of the common stock ($1.25) as reported by NASDAQ on December 30, 1998. DIRECTOR COMPENSATION FOR LAST FISCAL YEAR
Cash Compensation Security Grants ------------------------------------ --------------- NUMBER OF SECURITIES MEETING CONSULTING UNDERLYING NAME FEES(1) FEES(2) OPTIONS - ----------------------------------------------------- ----------- ------------ ------------- Stephen Chen, PhD $ 2,000 $ 45,950 5,000 James Cook 2,000 3,000 5,000 Thomas D'Alonzo 2,000 - 5,000 Katsuaki Hayashibara 2,000 -- 5,000 Brian McLean, MD 2,000 -- 5,000 Dennis Moore, DVM 2,000 4,500 5,000 James Page, MD 1,000 1,200 5,000
(1) Each director receives a fee of $1,000 for in-person attendance at each regular directors' meeting. (2) Each director receives $1,200 per day for employment on special projects or assignments. 3 4 ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT. As of December 31, 1998, there were 5,414,232 shares of the Company's common stock outstanding. The following table sets forth as of December 31, 1998, the beneficial ownership of each person who owns more than 5% of such outstanding common stock:
NAME AND ADDRESS NUMBER OF SHARES PERCENT OF TOTAL - ----------------------------------------------- ---------------- ---------------- Hayashibara Biochemical Laboratories, Inc. 2-3 Shimoishii 1-chome Okayama 700, Japan 1,232,856 22.8 Dr. Joseph Cummins 800 West 9th Avenue Amarillo, Texas 79101 676,814(1) 12.5 Mesa Operating Limited Partnership P.O. Box 2009 Amarillo, Texas 79189-2009 315,120 5.8 Mochida Pharmaceutical Co., Ltd. 7, Yotsuya 1-chome Shinjuku-Ku Tokyo 160, Japan 300,000 5.5
(1) Includes an aggregate of 337,668 shares of common stock held by Joseph Cummins as trustee under certain trusts for the benefit of his children and 10,590 shares owned by Dr. Cummins' wife. The following table sets forth the beneficial ownership of the Company's stock as of December 31, 1998 by each director, and by all executive officers and directors as a group:
DIRECTORS NUMBER OF SHARES PERCENT OF TOTAL - ---------------------------------- ---------------- ---------------- Joseph Cummins 676,814(1) 12.5 Dennis Moore 149,616 2.8 James Cook 66,600(2) 1.2 Katsuaki Hayashibara 48,240 1.0 Stephen Chen 9,400 * Thomas D'Alonzo 3,000 * Brian McLean -- -- James Page -- -- Total Group (all directors and executive officers - 8 persons) 953,670 17.6
* Less than 1% (1) Includes an aggregate of 337,668 shares of common stock held by Joseph Cummins as trustee under certain trusts for the benefit of his children and 10,590 shares owned by Dr. Cummins' wife. (2) All of such shares are owned jointly with Mr. Cook's wife. 4 5 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AMARILLO BIOSCIENCES, INC. By: /s/ JOSEPH M. CUMMINS ----------------------------------------------- Joseph M. Cummins, Chairman of the Board, President, Chief Financial Officer and Chief Executive Officer Date: April 6, 1999 ------------- Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature Title Date - --------- ----- ---- /s/ JOSEPH M. CUMMINS April 6, 1999 - ---------------------------- Chairman of the Board, ------------------------------ Joseph M. Cummins President, Chief Financial Officer, Director and Chief Executive Officer /s/ JAMES COOK Director April 6, 1999 - ---------------------------- ------------------------------ James Cook /s/ DENNIS MOORE Director April 6, 1999 - ---------------------------- ------------------------------ Dennis Moore /s/ JAMES PAGE Director April 6, 1999 - ---------------------------- ------------------------------ James Page /s/ THOMAS D'ALONZO Director April 6, 1999 - ---------------------------- ------------------------------ Thomas D'Alonzo
-----END PRIVACY-ENHANCED MESSAGE-----